SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00900185

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Retrospective Analysis of Endostatin Genotype in Prostate Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (D104N) in Endostatin and Prostate Cancer

RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA. PURPOSE: This laboratory study is looking at blood samples from patients with prostate cancer and from healthy participants to identify a polymorphism that may help in the study of prostate cancer.

NCT00900185 Prostate Cancer
MeSH:Prostatic Neoplasms
HPO:Prostate cancer Prostate neoplasm

3 Interventions

Name: mutation analysis

Type: Genetic

Name: polymerase chain reaction

Type: Genetic

Name: polymorphism analysis

Type: Genetic


Primary Outcomes

Measure: Frequency of D104N COL18A1 polymorphism in patients with prostate cancer and in healthy participants

Secondary Outcomes

Measure: Frequency of D104N COL18A1 polymorphism in African-American patients with prostate cancer and in healthy participants

There is one SNP

SNPs


1 D104N

Retrospective Analysis of Endostatin Genotype in Prostate Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (D104N) in Endostatin and Prostate Cancer. --- D104N ---

Frequency of D104N COL18A1 polymorphism in patients with prostate cancer and in healthy participants. --- D104N ---

Frequency of D104N COL18A1 polymorphism in African-American patients with prostate cancer and in healthy participants. --- D104N ---

DISEASE CHARACTERISTICS: - Diagnosis of prostate cancer OR healthy participant - Patient enrolled on an IRB-approved clinical trial at the National Cancer Institute or Northwestern University, including, but not limited to, any of the following: - NCI-99-C-0052 - NCI-95-C-0178 - NCI-00-C-003 - NCI-00-C-0080 PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified DISEASE CHARACTERISTICS: - Diagnosis of prostate cancer OR healthy participant - Patient enrolled on an IRB-approved clinical trial at the National Cancer Institute or Northwestern University, including, but not limited to, any of the following: - NCI-99-C-0052 - NCI-95-C-0178 - NCI-00-C-003 - NCI-00-C-0080 PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified Prostate Cancer Prostatic Neoplasms OBJECTIVES: Primary - Determine the incidence of the D104N COL18A1 polymorphism in patients with prostate cancer. --- D104N ---



HPO Nodes


HPO: